Cystic Fibrosis Study
Expanded Access Program for Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis and Pseudomonas aeruginosa Airway Infection Who Have Limited Treatment Options and are at Risk for Disease Progression
Protocol ID
Protocol Description
Cystic fibrosis (CF) is an inherited disease that causes thick, sticky mucus to build up in the lungs and digestive tract. People with CF often have lung infections that keep coming back or get worse. The purpose of this research study is to test an experimental drug called aztreonam lysine for inhalation (AZLI) on people with CF. Study investigators will provide AZLI to subjects with CF with lung infections who have been seen to respond well to the study drug and will monitor them for any serious side effects that they may experience.
Eligibility Criteria
People with cystic fibrosis (CF)
Primary Investigator(s)
- Rubin Cohen, MD, FACP, FCCP